We decided to exit the Oracle position and book a short-term tax loss, spreading the capital across several of the ...

How Low Is Too Low? (Downgrade, Technical Analysis) Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further Novo Nordisk: Full Kitchen Sink Reset Or Another Shoe Yet To Drop? Eli Lilly ...

It’s become clear that Big Pharma is not a friend of ordinary Americans. Prices are too high and have been rising for too ...

On February 9, Eli Lilly and Company (NYSE:LLY) announced an agreement to acquire Orna Therapeutics in a transaction valued ...

The Huntsville City Council is expected to finalize its agreement with Eli Lilly and Company on Thursday, bringing the largest private economic development project in state history to town.

Novo and Lilly are locked in a tightening fight in the obesity-drug market, with Novo trying to win back its crown after a ...

Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high ...

Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of February 6, 2026, robust demand for the company’s obesity and diabetes ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two ...

The Huntsville City Council will soon vote on a landmark $6 billion Eli Lilly campus, promising 450 jobs and significant economic growth in north Alabama.

A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company ...